Benitec Biopharma (NASDAQ:BNTC) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Benitec Biopharma (NASDAQ:BNTC) issued its quarterly earnings data on Friday. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01, FiscalAI reports.

Benitec Biopharma Price Performance

BNTC traded down $0.05 during trading on Friday, reaching $9.04. The company had a trading volume of 144,689 shares, compared to its average volume of 148,826. The company has a market cap of $315.41 million, a P/E ratio of -9.22 and a beta of 0.26. Benitec Biopharma has a 12 month low of $7.89 and a 12 month high of $14.39. The business’s fifty day moving average price is $9.74 and its 200 day moving average price is $11.41.

Analyst Upgrades and Downgrades

BNTC has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating on shares of Benitec Biopharma in a report on Monday, November 2nd. Wall Street Zen lowered shares of Benitec Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, September 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Benitec Biopharma in a research report on Thursday, October 15th. Citigroup restated a “market outperform” rating on shares of Benitec Biopharma in a research report on Tuesday, October 6th. Finally, Royal Bank Of Canada raised Benitec Biopharma to an “outperform” rating in a research note on Tuesday, September 15th. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $22.00.

About Benitec Biopharma

Benitec Biopharma is a clinical-stage biotechnology company developing genetic medicines for serious diseases. Its approach uses DNA-directed RNA interference (ddRNAi), a technique designed to reduce the production of disease-causing proteins by directing cells to silence specific genes. The company’s lead investigational candidate, BB-301, is being developed for oculopharyngeal muscular dystrophy (OPMD), a rare inherited disorder that can cause progressive muscle weakness and difficulty swallowing.